|Bid||21.81 x 2900|
|Ask||28.00 x 1300|
|Day's Range||23.03 - 23.54|
|52 Week Range||15.16 - 24.24|
|PE Ratio (TTM)||53.43|
|Earnings Date||Sep 27, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.50|
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Michael C.
AngioDynamics (ANGO) to benefit from a solid product portfolio. However, the company???s core Peripheral Vascular business has been sluggish.
AngioDynamics' (ANGO) agreement to acquire RadiaDyne is expected to close by the end of September. The RadiaDyne acquisition will expand the Oncology segment.
The transaction comes as AngioDynamics consolidates and expands its oncology business at its Glens Falls, New York, manufacturing complex.
AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the first quarter of fiscal year 2019 before the market open on Thursday, September 27, 2018.
AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes.
If you own shares in AngioDynamics Inc (NASDAQ:ANGO) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure ofRead More...
AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announc
NEW YORK, Aug. 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Okta, ...
AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today provided a corporate update on enhancements made to its Oncology business and acknowledged a recent, favorable U.S. District Court ruling that impacts its Vascular Access business. As part of its strategic focus on building a continuum of care within the oncology space, AngioDynamics has announced the acquisition of the BioSentry Tract Sealant System (BioSentry) technology from Surgical Specialties, LLC, a medical device company headquartered in Westwood, Massachusetts.
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
A New York-based medical device company will pay the U.S. government $12.5 million to resolve allegations that it had health care providers submit false claims to federal programs. The Department of Justice ...
AngioDynamics Inc has agreed to pay the U.S. government $12.5 million to resolve allegations it caused healthcare providers to submit false claims to federal healthcare programs over the use of two medical devices, the Justice Department said on Wednesday. The New York-based medical device maker will pay $11.5 million over allegations it was the distributor for Biocompatibles Plc of the LC Bead for use as a drug-delivery device in combination with chemotherapy drugs from May 2006 through December 2011, the department said in a statement.
LONDON, UK / ACCESSWIRE / July 18, 2018 / If you want access to our free earnings report on AngioDynamics, Inc. (NASDAQ: ANGO), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ANGO. The Company reported its financial results on July 11, 2018, for the fourth quarter and full fiscal year 2018. In addition, the Company provided its guidance for the full fiscal year 2019.
The Latham, New York-based company said it had profit of 6 cents per share. Earnings, adjusted for one-time gains and costs, were 20 cents per share. The medical device maker posted revenue of $88.3 million ...